NCT00163254Unknown2 期
Balloonangioplasty or Stents With ReoPro for Prevention of Subacute Reocclusion in Arteries Below the Knee
适应症
相关药物
试验速览
- 阶段
- 2 期
- 试验地点
- 2
- 主要终点
- The primary study objective is to demonstrate the superiority of an adjunctive administration of abciximab and drug eluting stents on the rate of subacute reocclusions at day 60 ± 10.
研究概览
简要总结
The Below-Study is a randomized, prospective mono-centre trial on the efficacy and safety the adjunctive use of a GP IIb/IIIa antagonist for prevention of early reocclusion in arterial below-the knee interventions.
详细描述
PTA below the knee is limited due to subacute reocclusions and uncertain long-term results. This study is designed as a feasibility trial, which compares the two new treatment modalities: drug eluting stents and GP IIb/IIIa blockade.
Patients with current ulcers (Rutherford 5, or 6) are randomly assigned to one of the treatment groups: [1] ReoPro + Sirolimus coated stent, [2] ReoPro + bare Stent, [3] ReoPro + PTA, [4] PTA without ReoPro. Angiographic control will be at 2 and 6 months with block wise randomisation to the treatment groups.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 95 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with a history of peripheral artery disease with below the knee artery occlusion, or stenosis which mandates PTA or stent administration as first treatment modality. The history of peripheral artery occlusion has to at least 6 weeks, and the target vessel occlusion has to be no longer than 5 centimeters in length (corresponding to a maximum of 2 stents per treated lesion). The number of treated lesions per vessel in this study is limited to three. Only the major lesion will be allocated to one of the study groups, the other lesions will be treated by conventional PTA. A documentation of distal outflow (no occlusion until 3 cm above the upper joint ankle) is mandatory
- •Severe stage of PAD with ulceration(s) corresponding to Rutherford stage 5 or 6.
排除标准
- •Acute limb ischemia
- •Subacute ischemia with requires thrombolysis as first treatment modality
- •Active bleeding or known bleeding diathesis
- •Known severe hepatic or renal disorder (liver cirrhosis, stage B, C or serum creatinine > 2.5 mg%)
- •Hyperthyreosis
- •Diabetes mellitus treated with metformin
- •Known heparin induced thrombocytopenia (HIT, type 2)
- •Major surgery, eye surgery or trauma within past 6 weeks
- •History of stroke within the previous 2 years, or any stroke with a residual neurological deficit, or other CNS abnormality (e.g., intracranial neoplasm, arteriovenous malformation, or aneurysm), or history of aneurysm repair
- •Gastrointestinal or genitourinary bleeding of clinical significance within the previous 6 weeks
- •Puncture of a non compressible vessel within past 24 hours
- •Administration of oral anticoagulants within the previous 7 days unless prothrombin time is < 1.2 times control (or international normalized ratio [INR] <1.4), or ongoing treatment with oral anticoagulants
- •History of bleeding diathesis of platelet count < 100,000/mm3
- •Known ReoPro-induced thrombocytopenia
- •Arteriovenous malformations or aneurysms
- •Severe uncontrolled hypertension (treated sys. BP > 200 mm Hg, diast. BP > 100 mm Hg)
- •Known autoimmune disorders
- •Patient with vasculitis
- •Patient with aspirin intolerance
- •Contraindication or known allergic reactions to rapamycin, abciximab or murine proteins
- •Co-existent condition associated with a limited life expectancy (e.g., advanced cancer, end-stage congestive heart failure)
- •Women of child-bearing potential with a positive pregnancy test
- •Patient in prison or any vulnerable patient (soldier,...) as defined in the declaration of Helsinki
结局指标
主要结局
The primary study objective is to demonstrate the superiority of an adjunctive administration of abciximab and drug eluting stents on the rate of subacute reocclusions at day 60 ± 10.
次要结局
- The binary restenosis rate (restenosis > 50%) at 6 months
- The rate of mortality, amputation (including toes), repeat target vessel intervention, and healing of ulcers 2 and 6 months from randomization.
- Quality of life assessment 2 and at 6 months compared to baseline
- Change in ankle brachial index (ABI) after the intervention, at 2 and at 6 months.
- Change in Rutherford stages at 2 and at 6 months compared to baseline.
- Hospital days for index hospitalization
- Hospital days for repeat revascularization and amputation at 2 and 6 months
- Safety analysis
研究者
研究点 (2)
Loading locations...
相似试验
已完成
不适用
Tack Optimized Balloon Angioplasty Study of the Tack Endovascular System™ in Femoropoliteal ArteriesPeripheral Artery DiseaseNCT02522884Philips Clinical & Medical Affairs Global213
已完成
不适用
Tack Optimized Balloon Angioplasty Study of the Tack Endovascular System® in Below the Knee ArteriesPeripheral Arterial DiseaseNCT02942966Philips Clinical & Medical Affairs Global233
招募中
不适用
TWIN2WIN (Double Stent (DS-EVT) Versus Primary Thrombectomy With One Stent (SS-EVT))Acute Ischemic StrokeNCT05632458Hospital Universitari Vall d'Hebron Research Institute180
招募中
不适用
Clinical Of Plain Balloon Dilatation Combined Stent Versus Endovascular Debulking Combined Drug-coated Balloon to Treat Arteriosclerosis Occlusive Disease of Lower ExtremityIschemiaAtherosclerosisNCT05158257Xuanwu Hospital, Beijing144
Unknown
不适用
Scoring-Balloon Angioplasty and Sirolimus-Eluting Balloon Angioplasty for the Treatment of Diffuse, Small Vessel Coronary Artery Disease (SCA-DEB Study)Coronary Artery DiseaseNCT06197022University National Heart Hospital106